HER-2/Neu Serum Levels and Menopausal Status

Rajkumar T. , Gullick W.J. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994; 29: 3–9.

Revillion F. , Bonneterre J. , Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791–808.

Mori S. , Mori Y. , Mukalyama T. In vitro and in vivo release of soluble erbB2 protein from human carcinoma cells. Jpn J Cancer Res 1990; 81: 489–94.

Yamauchi H. , O'Neill A. , Gelman R. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 2518–25.

Shak S. Overview of the Trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in Her-2 overexpressing metastatic breast cancer. Semin Oncol 1999; 26: 71–77.

Harris L. , Luftner D. , Jager W. , Robertson J.F.R. C-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 1999; 14: 8–15.

Meden H. , Mielke S. , Marx D. , Wuttke W. , Kuhn W. Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 1997; 17: 3075–80.

Mielke S. , Meden H. , Raab T. , Wuttke W. , Kuhn W. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res 1997; 17: 3125–8.